Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$7.8MFederal grants as PI14 awards
1Patents grantedLatest Jan 10, 2017
53Papers2,268 citations
Federal awards and patents by year
AwardsPatents
14 awards · $7.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 25, 2026 | NIH | STTR Phase I Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections | $299K | MICROBIOTIX, INC. |
| Sep 20, 2025 | NIH | STTR Phase I Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections | $300K | MICROBIOTIX, INC. |
| Apr 14, 2025 | NIH | STTR Phase I Proof of concept experiments for T3SS inhibitors against burn wound infections | $300K | MICROBIOTIX, INC. |
| Apr 12, 2024 | NIH | STTR Phase I Proof of concept experiments for T3SS inhibitors against burn wound infections | $300K | MICROBIOTIX, INC. |
| May 27, 2022 | NIH | SBIR Phase I Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis | $300K | MICROBIOTIX, INC. |
| Aug 26, 2021 | NIH | SBIR Phase II Optimization of novel pyranopyridine efflux pump inhibitors | $1.0M | MICROBIOTIX, INC. |
| Jul 13, 2021 | NIH | STTR Phase I Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa | $300K | MICROBIOTIX, INC. |
| Jul 31, 2020 | NIH | SBIR Phase II Optimization of novel pyranopyridine efflux pump inhibitors | $981K | MICROBIOTIX, INC. |
| Aug 20, 2019 | NIH | SBIR Phase II Optimization of novel pyranopyridine efflux pump inhibitors | $988K | MICROBIOTIX, INC. |
| May 31, 2018 | NIH | SBIR Phase I Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance | $295K | MICROBIOTIX, INC. |
| May 23, 2017 | NIH | SBIR Phase I Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance | $299K | MICROBIOTIX, INC. |
| Jan 23, 2017 | NIH | SBIR Phase II Optimization of novel pyranopyridine efflux pump inhibitors | $743K | MICROBIOTIX, INC. |
| Jan 15, 2016 | NIH | SBIR Phase II Optimization of novel pyranopyridine efflux pump inhibitors | $783K | MICROBIOTIX, INC. |
| Feb 9, 2015 | NIH | SBIR Phase II Optimization of novel pyranopyridine efflux pump inhibitors | $961K | MICROBIOTIX, INC. |
2 patents as inventor
- US 9540389MICROBIOTIX, INC.Jan 10, 2017
- US MICROBIOTIX, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#117
Awards as PI#57
Patents#155
Companies
- MICROBIOTIX, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.